Euphrates Vascular

Euphrates Vascular, based in St. Louis, was founded through the merger of Pulse Therapeutics and ICHOR Vascular. The company's core mission is to revolutionize the treatment of vascular diseases using advanced magnet-based technology. Their flagship product, the Pulse NanoMED™ System, is a nanoscale interventional device designed to diagnose and treat complex vascular occlusions that are otherwise unreachable with traditional methods. Euphrates Vascular aims to significantly improve patient outcomes for conditions like stroke by accelerating the delivery of clot-busting drugs.

Notable affiliated individuals include the founders and key medical advisors from both Pulse Therapeutics and ICHOR Vascular, who bring extensive expertise in vascular health and medical device innovation. The company has attracted significant investment from healthcare-focused venture capital firms. Key achievements include the development and patenting of their Magnetically-Enhanced Diffusion system, which has shown promising results in preclinical trials. Euphrates Vascular's impact lies in its potential to transform vascular disease treatment, offering faster and more effective solutions for life-threatening conditions.